{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:57:05Z","timestamp":1790143025500,"version":"4.0.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2022MH322"],"award-info":[{"award-number":["ZR2022MH322"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Plan","award":["673 and 741"],"award-info":[{"award-number":["673 and 741"]}]},{"name":"Clinical Medical Science and Technology Development Plan","award":["202019186"],"award-info":[{"award-number":["202019186"]}]},{"name":"Horizontal issues of Shandong University","award":["6020121011"],"award-info":[{"award-number":["6020121011"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>To investigate the efficacy and safety of rituximab (RTX) with or without glucocorticoid (GC) in inducing remission of minimal change disease (MCD) in adults.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Twenty-one adult MCD patients were included in the study. The patients were assigned to the following three groups according to their background before RTX treatment: an RTX single drug direct induction treatment group (Group A; n\u00a0=\u00a09), a short-term, low-dose GC combined with RTX induction treatment group (Group B; n\u00a0=\u00a04), and a short-term, adequate-dose GC-induced remission and RTX maintenance treatment group (Group C; n\u00a0=\u00a08). The primary endpoints were the time to induction of remission and the rate of clinical remission at 12\u00a0months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All patients achieved clinical remission, with 19 (90.48%) achieving complete remission (CR), and the median remission time was 4 (2.5, 12) weeks. Eight (88.89%) patients in Group A achieved CR, and the median remission time was 3 (2.25, 14) weeks. In Group B, three (75.00%) patients achieved CR, with a median remission time of 4 (4, 10) weeks. In Group C, eight (100.00%) patients achieved CR, and the median remission time was 3.5 (2, 4) weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In MCD patients without acute kidney injury, adequate RTX alone or short-term combined treatment with low-dose GCs can effectively induce and maintain MCD remission. Adequate short-term GCs combined with RTX maintenance may be an effective alternative for MCD patients in context of acute kidney injury. There is a need to investigate different induction therapy regimens for the remission of MCD patients with different backgrounds.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfae139","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T03:26:17Z","timestamp":1714793177000},"source":"Crossref","is-referenced-by-count":9,"title":["The efficacy and safety of rituximab with or without glucocorticoid in inducing remission of MCD with different clinical presentations in adults: a retrospective study"],"prefix":"10.1093","volume":"17","author":[{"given":"Yujiao","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University , Jinan, Shandong , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University , Jinan, Shandong , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University , Jinan, Shandong , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University , Jinan, Shandong , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University , Jinan, Shandong , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University , Jinan, Shandong , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"2024060808353025900_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0272-6386(87)80170-1","article-title":"The nephrotic syndrome and its complications","volume":"10","author":"Cameron","year":"1987","journal-title":"Am J Kidney Dis"},{"key":"2024060808353025900_bib2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2215\/CJN.05000516","article-title":"Minimal change disease","volume":"12","author":"Vivarelli","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024060808353025900_bib3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ki.1991.232","article-title":"A glomerular permeability factor produced by human T cell hybridomas","volume":"40","author":"Koyama","year":"1991","journal-title":"Kidney Int"},{"key":"2024060808353025900_bib4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","article-title":"Pathogenesis of lipoid nephrosis: a disorder of T-cell function","volume":"2","author":"Shalhoub","year":"1974","journal-title":"Lancet"},{"key":"2024060808353025900_bib5","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00467-011-1947-1","article-title":"Physiopathology of idiopathic nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives","volume":"27","author":"Elie","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"2024060808353025900_bib6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.clim.2011.02.018","article-title":"Th17\/Treg imbalance in adult patients with minimal change nephrotic syndrome","volume":"139","author":"Liu","year":"2011","journal-title":"Clin Immunol"},{"key":"2024060808353025900_bib7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/s13063-021-05393-4","article-title":"A randomised controlled unblinded multicentre non-inferiority trial with activated vitamin D and prednisolone treatment in patients with minimal change nephropathy (ADAPTinMCN)","volume":"22","author":"Kristensen","year":"2021","journal-title":"Trials"},{"key":"2024060808353025900_bib8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2024060808353025900_bib9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"2024060808353025900_bib10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1053\/j.ajkd.2016.10.032","article-title":"The clinical course of minimal change nephrotic syndrome with onset in adulthood or late adolescence: a case series","volume":"69","author":"Maas","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2024060808353025900_bib11","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2215\/CJN.05691108","article-title":"Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children","volume":"4","author":"Kyrieleis","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024060808353025900_bib12","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.2215\/CJN.05500610","article-title":"Rituximab treatment for vasculitis","volume":"5","author":"Jayne","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024060808353025900_bib13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000486930","article-title":"Rituximab as a therapeutic option for steroid-sensitive minimal change nephrotic syndrome in adults","volume":"195","author":"Iwabuchi","year":"2018","journal-title":"Contrib Nephrol"},{"key":"2024060808353025900_bib14","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.imbio.2016.11.011","article-title":"Kinetic analysis of changes in T- and B-lymphocytes after anti-CD20 treatment in renal pathology","volume":"222","author":"Sent\u00eds","year":"2017","journal-title":"Immunobiology"},{"key":"2024060808353025900_bib15","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/ndt\/gfz205","article-title":"Rituximab in minimal change disease and focal segmental glomerulosclerosis","volume":"36","author":"Kronbichler","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2024060808353025900_bib16","doi-asserted-by":"crossref","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","article-title":"Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis","volume":"3","author":"Fornoni","year":"2011","journal-title":"Sci Transl Med"},{"key":"2024060808353025900_bib17","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2147\/DDDT.S302257","article-title":"Consolidation treatment and long-term prognosis of rituximab in minimal change disease and focal segmental glomerular sclerosis","volume":"15","author":"Lin","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"2024060808353025900_bib18","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2024060808353025900_bib19","doi-asserted-by":"crossref","first-page":"28799","DOI":"10.18632\/oncotarget.25612","article-title":"Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome","volume":"9","author":"Fenoglio","year":"2018","journal-title":"Oncotarget"},{"key":"2024060808353025900_bib20","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/14712598.2019.1665017","article-title":"Rituximab biosimilars for lymphoma in Europe","volume":"19","author":"Jurczak","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"2024060808353025900_bib21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40259-021-00487-6","article-title":"Factors influencing infusion-related reactions following dosing of reference rituximab and PF-05280586, a rituximab biosimilar","volume":"35","author":"Courville","year":"2021","journal-title":"BioDrugs"},{"key":"2024060808353025900_bib22","doi-asserted-by":"crossref","first-page":"572863","DOI":"10.3389\/fphar.2020.572863","article-title":"Rituximab hypersensitivity: from clinical presentation to management","volume":"11","author":"Fouda","year":"2020","journal-title":"Front Pharmacol"},{"key":"2024060808353025900_bib23","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ekir.2023.02.1070","article-title":"Rituximab as initial therapy in adult patients with minimal change disease","volume":"8","author":"Guan","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2024060808353025900_bib24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2215\/CJN.03531006","article-title":"Adult minimal-change disease: clinical characteristics, treatment, and outcomes","volume":"2","author":"Waldman","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024060808353025900_bib25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2215\/CJN.06180519","article-title":"Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: a multicenter, randomized, controlled trial","volume":"15","author":"Medjeral-Thomas","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024060808353025900_bib26","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ckj\/sfaa191","article-title":"Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis","volume":"14","author":"Xue","year":"2021","journal-title":"Clin Kidney J"},{"key":"2024060808353025900_bib27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1681\/ASN.2021050643","article-title":"Mycophenolate mofetil after rituximab for childhood-onset complicated frequently-relapsing or steroid-dependent nephrotic syndrome","volume":"33","author":"Iijima","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2024060808353025900_bib28","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1681\/ASN.2021040561","article-title":"Human or chimeric monoclonal anti-CD20 antibodies for children with nephrotic syndrome: a superiority randomized trial","volume":"32","author":"Ravani","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2024060808353025900_bib29","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/nep.13554","article-title":"Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy","volume":"24","author":"Ramachandran","year":"2019","journal-title":"Nephrology"},{"key":"2024060808353025900_bib30","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae139\/57400265\/sfae139.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/6\/sfae139\/58173528\/sfae139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/6\/sfae139\/58173528\/sfae139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T08:37:33Z","timestamp":1717835853000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae139\/7664386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae139","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,5,3]]},"article-number":"sfae139"}}